Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience Inc. (VIGL) is a pioneering biotechnology company developing novel therapies that target microglia dysfunction in neurodegenerative diseases. This dedicated news hub provides investors and researchers with timely updates on clinical trials, scientific advancements, and strategic developments.
Access comprehensive coverage of VIGL's progress in Alzheimer's research, rare neurological disorders, and innovative treatment approaches. Our curated collection includes earnings reports, regulatory milestones, partnership announcements, and analysis of therapeutic pipeline developments.
Key updates feature progress on the company's TREM2 agonist programs, monoclonal antibody therapies, and biomarker validation studies. Stay informed about clinical trial phases, research collaborations, and scientific presentations through verified press releases and objective reporting.
Bookmark this page for streamlined access to essential VIGL updates. Combine our news monitoring with SEC filings and investor resources for complete due diligence on this microglia-focused biotech innovator.
Vigil Neuroscience (Nasdaq: VIGL) announced the lifting of FDA's partial clinical hold on doses over 20 mg/kg for its lead candidate, VGL101, aimed at treating adult-onset leukoencephalopathy (ALSP). The decision follows favorable data from an ongoing Phase 1 trial. Vigil plans to present interim Phase 2 trial data in the second half of 2023. VGL101 is currently in the IGNITE trial, with initial findings expected for six patients. The FDA has previously awarded Fast Track and Orphan Drug designations to VGL101, highlighting its potential in addressing the unmet medical needs of ALSP, which affects around 10,000 individuals in the U.S.
Vigil Neuroscience (Nasdaq: VIGL) announced that Ivana Magovčević-Liebisch, Ph.D., J.D., its CEO, will participate in a fireside chat at the Stifel 2023 CNS Days virtual conference on March 29, 2023, at 12:00 p.m. ET. Investors can access the live webcast through the 'Events & Presentations' section on the company's website, with an archived replay available for 90 days post-event.
The company focuses on developing treatments for neurodegenerative diseases using microglia. Its lead candidate, VGL101, is in a Phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and it is also exploring treatments for Alzheimer's disease.
Vigil Neuroscience (Nasdaq: VIGL) dosed its first patient in the IGNITE Phase 2 clinical trial for VGL101, targeting adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In 2022, the company reported significant progress, including interim data from the Phase 1 trial showing VGL101 was safe and well-tolerated, and interim findings from the ILLUMINATE study indicating greater disease progression in symptomatic versus prodromal ALSP patients. Financially, Vigil ended 2022 with cash of $186.6 million, projected to fund operations into Q1 2025. R&D expenses increased to $47.4 million, reflecting clinical trial advancements.
FAQ
What is the current stock price of Vigil Neuroscience (VIGL)?
What is the market cap of Vigil Neuroscience (VIGL)?
